Timing of ctDNA Testing in Advanced Breast Cancer

Conditions

• Advanced Breast Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced breast cancer.

Key Dates

First listed

Jul 2, 2026

Start date

Jul 8, 2026

Status verified

Jul 2026

Primary completion

Jun 30, 2027

Completion

Jun 30, 2029

Study Design

Enrollment

400 participants (estimated)

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: From diagnosis until death or study completion, up to 3 years ]

Central Contacts

• Fei Ma, MD
  +8615010127581
  [email protected]

Related Studies

• Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Fairway, Kansas
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  PHASE1 · Recruiting · Relay Therapeutics, Inc. · Tucson, Arizona
• Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
  PHASE2 · Recruiting · Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire
• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
  PHASE3 · Recruiting · Olema Pharmaceuticals, Inc. · Tucson, Arizona